No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
UTHR240517C200000
- 73.37
- -0.33-0.45%
15min DelayClose May 17 16:00 ET
73.37High73.37Low
73.37Open73.70Pre Close10 Volume10 Open Interest200.00Strike Price73.37KTurnover0.00%IV0.00%PremiumMay 17, 2024Expiry Date74.26Intrinsic Value100Multiplier0DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma3.69Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
United Therapeutics(UTHR.US) Director Sells US$545.8K in Common Stock
$United Therapeutics(UTHR.US)$ Director CAUSEY CHRISTOPHER sold 2,000 shares of common stock on May 15, 2024 at an average price of $272.9 for a total value of $545.8K.Source: Announcement What is sta
United Therapeutics(UTHR.US) Officer Sells US$10.95 Million in Common Stock
$United Therapeutics(UTHR.US)$ Officer EDGEMOND JAMES sold 40,160 shares of common stock on May 15, 2024 at an average price of $272.69 for a total value of $10.95 million.Source: Announcement What is
United Therapeutics(UTHR.US) Officer Sells US$1.95 Million in Common Stock
$United Therapeutics(UTHR.US)$ Officer ROTHBLATT MARTINE A sold 7,200 shares of common stock on May 14, 15, 2024 at an average price of $270.3503 for a total value of $1.95 million.Source: Announcemen
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing
Christopher Causey, Director, on May 15, 2024, sold 2,000 shares in United Therapeutics (UTHR) for $545,800. Following the Form 4 filing with the SEC, Causey has control over a total of 4,185 shares o
United Therapeutics(UTHR.US) Director Sells US$346.3K in Common Stock
$United Therapeutics(UTHR.US)$ Director PATUSKY CHRISTOPHER sold 1,310 shares of common stock on May 14, 2024 at an average price of $264.35 for a total value of $346.3K.Source: Announcement What is s
Form 144 | United Therapeutics(UTHR.US) Director Proposes to Sell 545.58K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $United Therapeutics(UTHR.US)$ Director CHRISTOPHER CAUSEY intends to sell 2,000 shares of its common stock on May 15, with a total market value of approximately $545.5
Comments
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
10
1
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
Are you a high net profit margin lover? So you will like these 1⃣2⃣ stocks with a net profit margin above 4⃣0⃣%
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8%...
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8%...
13
The low P/E despite solid growth numbers seems to stem from investor sentiment, possibly from certain unobserved threats affecting the stock. Some shareholders might be skeptical of the earnings forecasts, indicating potential earnings instability.
United Therapeutics' strong financials could suggest long-term stock increase. Its net income growth might be due to good management and a low payout ratio, even though the earnings growth may slow down in future.
Read more
Jimmy1819 : have you been investing professionally or as a hobby?